Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS)

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 3, 2002, Pages 285-292

  Deters, Michael ^a   Kirchner, Gabriele ^a   Resch, Klaus ^a   Kaever, Volkhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclosporine; Everolimus; Immunosuppressants; LC MS; Sirolimus; Tacrolimus

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; METHANOL; RAPAMYCIN; SODIUM ION; TACROLIMUS; WATER;

ACCURACY; ARTICLE; AUTOMATION; CENTRIFUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ONLINE SYSTEM; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUPERNATANT; TEMPERATURE; VORTEX MOTION;

BLOOD CHEMICAL ANALYSIS; CALIBRATION; CHROMATOGRAPHY, LIQUID; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; MASS SPECTROMETRY; SIROLIMUS; TACROLIMUS; TEMPERATURE; TIME FACTORS;

EID: 0036238215     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.045     Document Type: Article

References (42)

1. Cyclosporine
2. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders
3. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation
4. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
5. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation
6. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine
7. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection
8. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
9. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
10. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability
11. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
12. Sirolimus-tacrolimus combination immunosuppression
13. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
14. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
15. P-glycoprotein and drug therapy in organ transplantation
16. Current opinions on therapeutic drug monitoring of immunosuppressive drugs
17. Rapamycin: Clinical results and future opportunities
18. Sirolimus: A new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation
19. Therapeutic monitoring of tacrolimus
20. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and EMIT): A critical overview of performance characteristics and comparison with HPLC
21. Therapeutic drug monitoring of cyclosporine and tacrolimus
22. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients
23. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants
24. Comparison of cyclosporine in whole blood by high-performance liquid chromatography, monoclonal fluorescent polarization immunoassay, and monoclonal enzyme-multiplied immunoassay
25. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone
26. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin
27. Immunosuppressive activity of cyclosporine metabolites in vitro
28. Cyclosporin metabolism in transplant patients
29. Therapeutic drug monitoring of immunosuppressant drugs
30. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes
31. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin
32. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients
33. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay
34. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry
35. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay
36. Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood
37. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry
38. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry
39. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants
40. A simple rapid lc-ms/ms method for simultaneous quantification of sirolimus, tacrolimus, everolimus and CsA
41. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection
42. Fast quantification method for sirolimus and its major metabolites